LP
XENE icon

LMR Partners’s Xenon Pharmaceuticals XENE Stock Holding History

LMR Partners’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.27M Buy
+56,200
New +$2.59M 0.01% 754
2025
Q1 		– Sell
-48,668
Closed -$1.91M – 1667
2024
Q4 		$1.91M Hold
48,668
– – 0.02% 618
2024
Q3 		$1.92M Hold
48,668
– – 0.02% 619
2024
Q2 		$1.9M Hold
48,668
– – 0.02% 556
2024
Q1 		$2.1M Buy
48,668
+47,710
+4,980% +$2.19M 0.02% 540
2023
Q4 		$44.1K Sell
958
-24,042
-96% -$849K ﹤0.01% 801
2023
Q3 		$854K Buy
+25,000
New +$935K 0.01% 508
2023
Q1 		– Sell
-50,000
Closed -$1.97M – 1173
2022
Q4 		$1.97M Sell
50,000
-15,698
-24% -$572K 0.03% 539
2022
Q3 		$2.37M Sell
65,698
-34,302
-34% -$1.23M 0.04% 483
2022
Q2 		$3.04M Buy
+100,000
New +$3.02M 0.05% 401

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

LMR Partners's XENE Position: Q1 2026 in Review

LMR Partners opened a new position in Xenon Pharmaceuticals (XENE) in Q1 2026: 56,200 shares worth $3.27M. The stake represents 0.01% of the portfolio and ranks #754 among its holdings. This is a return to the name: LMR Partners previously reported a position in XENE as recently as Q4 2024.

LMR Partners first reported a position in XENE in Q2 2022 and has held it in 10 quarters since. 290 funds tracked by Wall St. Rank hold XENE as of Q1 2026.

  • LMR Partners held 56,200 shares of Xenon Pharmaceuticals worth $3.27M as of Q1 2026.
  • Xenon Pharmaceuticals was a new LMR Partners position in Q1 2026.
  • Xenon Pharmaceuticals made up 0.01% of LMR Partners's portfolio in Q1 2026, its #754 holding.
  • LMR Partners first reported a position in Xenon Pharmaceuticals in Q2 2022 and has held it in 10 quarters since.
  • 290 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q1 2026.

Based on LMR Partners's 13F filing for Q1 2026, filed 15 May 2026.